In conclusion, the efficacy of bumetanide to improve memory deficits in the APOE4 genetic condition of AD and evidence for its clinical effectiveness to reduce the incidence of AD provide compelling support for further clinical investigation of bumetanide as a repurposed therapeutic for ameliorating AD deficits. This evidence concerns the gene APOE and Alzheimer disease.